Cargando…

Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)

A biosimilar is a biological medicinal product that contains a version of the active substance of an already authorized original biological medicinal product. Biosimilarity to the reference product (RP) in terms of quality characteristics, such as physicochemical and biological properties, safety, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Juyong, Lee, Yuhwa, Lee, Changsoo, Eo, Suhyeon, Kim, Soyeon, Lee, Nayoung, Park, Jongmin, Park, Seungkyu, Seo, Donghyuck, Jeong, Min, Lee, Youngji, Yeon, Soojeong, Bou-Assaf, George, Sosic, Zoran, Zhang, Wei, Jaquez, Orlando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297515/ https://www.ncbi.nlm.nih.gov/pubmed/28005456 http://dx.doi.org/10.1080/19420862.2016.1264550

Ejemplares similares

Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab)
por: Derzi, Mazin, et al.
Publicado: (2016)

Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®
por: Lee, Changsoo, et al.
Publicado: (2017)

Infliximab (Remicade) in the treatment of psoriatic arthritis
por: Mease, Philip
Publicado: (2006)

A descriptive analysis of real-world treatment patterns of innovator (Remicade(®)) and biosimilar infliximab in an infliximab-naïve Turkish population
por: Yazici, Yusuf, et al.
Publicado: (2018)

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
por: Cho, Ick Hyun, et al.
Publicado: (2016)

Remicade(®) (infliximab): 20 years of contributions to science and medicine
por: Melsheimer, Richard, et al.
Publicado: (2019)

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
por: Choe, Jung-Yoon, et al.
Publicado: (2017)

A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects
por: Shin, Donghoon, et al.
Publicado: (2015)

A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade(®))
por: Kim, Soohyun, et al.
Publicado: (2020)

Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents
por: Reinisch, Walter, et al.
Publicado: (2017)

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)

Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar
por: Lee, JongAh Joanne, et al.
Publicado: (2023)

The efficacy and safety of the biosimilar product (Inflectra(®)) compared to the reference drug (Remicade(®)) in rescue therapy in adult patients with ulcerative colitis
por: Kaniewska, Magdalena, et al.
Publicado: (2017)

Long-Term Clinical Outcomes After Switching from Remicade(®) to Biosimilar CT-P13 in Inflammatory Bowel Disease
por: Smits, Lisa J. T., et al.
Publicado: (2017)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
por: Tanaka, Y, et al.
Publicado: (2010)

The Use of Infliximab (Remicade®) for the Treatment of Rheumatic Diseases at a Tertiary Center in Lebanon: A 17-Year Retrospective Chart Review
por: Nahra, Vicky, et al.
Publicado: (2020)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea
por: Kim, Dong W., et al.
Publicado: (2023)

Advanced assessment through intact glycopeptide analysis of Infliximab’s biologics and biosimilar
por: Kim, Hyejin, et al.
Publicado: (2022)

PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Twenty Years of Quiescence after Nonstop Remicade(®) (Infliximab) Infusions in a Child with Ocular Behçet Disease Presenting as Hypopyon-Anterior Uveitis Refractory to Immunosuppressants
por: Evereklioglu, Cem
Publicado: (2023)

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels
por: Magro, F., et al.
Publicado: (2018)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study
por: Fautrel, Bruno, et al.
Publicado: (2023)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
por: Peng, Kuan, et al.
Publicado: (2023)

Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
por: Lerch, Thomas F., et al.
Publicado: (2019)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
por: Peters, Bas J. M., et al.
Publicado: (2021)

Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
por: Alanaeme, Chibuike J., et al.
Publicado: (2022)

Chronic Inflammatory Demyelinating Polyneuropathy After Therapy With Infliximab Biosimilar
por: Larson, Jessica, et al.
Publicado: (2023)

In-Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period
por: Tak, Minji, et al.
Publicado: (2023)

The process defines the product: what really matters in biosimilar design and production?
por: Vulto, Arnold G., et al.
Publicado: (2017)

Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study
por: Park, Eun Hye, et al.
Publicado: (2018)

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2019)

PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients
por: Martinez-Vinson, Christine, et al.
Publicado: (2022)

Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb
por: Bhat, Shubha, et al.
Publicado: (2020)

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study
por: Smolen, Josef S, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qlrljrilhul6gt43vn51b8rg8n